TVGN | Tevogen Bio Holdings Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.4000 - 1.7600
52 Week Range	0.2560 - 21.09
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	20,644,159
Average Volume	15,893,879
Shares Outstanding	170,646,870
Market Cap	242,318,555
Sector	Healthcare
Industry	Biotechnology
IPO Date	2022-01-05

Valuation
Profitability
Growth
Health
P/E Ratio	23.67
Forward P/E Ratio	N/A
EPS	0.06
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	17
Country	USA
Website	TVGN

Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.

*Chart delayed

Analyzing fundamentals for TVGN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see TVGN Fundamentals page.

Watching at TVGN technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullish short-term trend. More technicals details can be found on TVGN Technicals page.